Study of TP-3654 in Patients With Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
TP-3654 is an oral PIM inhibitor. This is a Phase 1, open-label, dose-escalation, safety,
pharmacokinetics, and pharmacodynamic study, with a purpose of determining the maximum
tolerated dose (MTD) and dose-limiting toxicities (DLTs) of oral TP-3654 in patients with
advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Sumitomo Dainippon Pharma Oncology, Inc Tolero Pharmaceuticals, Inc.